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a b s t r a c t
Objective: We investigated the relationship between anxiety and event-free
survival (ie, composite endpoint of death, emergency department visits, or
hospitalizations) for patients with heart failure (HF), and examined whether
behavioral and physiologic mechanisms mediate any association between
anxiety and outcomes.
Methods: In this longitudinal study, patients with HF completed the anxiety
subscale of the Brief Symptom Inventory, and heart-rate variability and plasma
norepinephrine levels were measured. Dietary adherence and medication
adherence were measured according to 24-hour urine sodium level and the
Medication Event Monitoring System, respectively. Patients were followed at
least 1 year for event-free survival.
Results: In total, 147 patients were enrolled. Patients with high anxiety had
a shorter (hazard ratio, 2.2; 95% confidence interval, 1.1-4.3; P ¼ .03) period of
event-free survival than patients with lower anxiety. Anxiety independently
predicted adherence to medication (P ¼ .008), which in turn predicted event-free
survival (hazard ratio, 2.0; 95% confidence interval, 1.2-3.3; P ¼ .008). The effect
of anxiety (P ¼ .17) on event-free survival was less significant when the
regression model included both anxiety and adherence to medication than
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when the model only included anxiety (P ¼ .03), indicating that adherence to
medication mediated the relationship between anxiety and event-free survival.
Conclusion: This is the first study to show that nonadherence to medication
links anxiety and event-free survival for patients with HF. Interventions that
reduce anxiety and improve adherence may benefit outcomes.
Cite this article: De Jong, M. J., Chung, M. L., Wu, J.-R., Riegel, B., Rayens, M. K., & Moser, D. K. (2011,
SEPTEMBER/OCTOBER). Linkages between anxiety and outcomes in heart failure. Heart & Lung, 40(5), 393-
404. doi:10.1016/j.hrtlng.2011.02.002.
More than 5,700,000 Americans have heart failure (HF),
a chronic condition that contributes to more than
292,000 deaths annually.1 The effects of demographic,
clinical, and treatment characteristics on outcomes are
well-studied. Improved outcomes were associated
with the use of angiotensin-converting enzyme (ACE)
inhibitors,2 b-adrenergic blockers,3 angiotensin
receptor blockers,4 aldosterone inhibitors,5 mechanical
circulatory support devices,6 ventricular reconstruc-
tion surgery,7 cardiac resynchronization therapy,8
nutritional therapy,9 and disease management.10
Nonetheless, hospitalizations for HF continue to rise.11
Patients with cardiac disease, including HF, often
experience high levels of anxiety.12-17 Anxiety was
linked to adverse outcomes for patients with an acute
myocardial infarction (AMI),18,19 but the link between
anxiety and outcomes is not well-established in HF.20
Although the mechanisms whereby anxiety may be
associated with cardiac outcomes are unclear,13
evidence suggests that behavioral and physiologic
pathways (Figure 1) may link anxiety and adverse
outcomes.13
One physiologic model accounts for the relation-
ships between psychological factors and heart disease
outcomes.21 According to the model, psychological
factors, such as anxiety, stimulate sympathetic
nervous system (SNS) activity and catecholamine
release that, in time, produce harmful consequences.
Elevated levels of plasma norepinephrine, which
provide the standard biochemical method of assessing
the severity of SNS activation, predict mortality for
patients with HF.22 For patients with AMI, but not
healthy persons, elevated plasma norepinephrine
levels were positively correlated with anxiety.23 Others
demonstrated that although patients with HF had
higher baseline sympathetic activity and heart rates
than healthy persons, patients with HF manifested
even higher sympathetic activity and heart rates
during mental stress, which is considered an equiva-
lent to anxiety.24 Controlling for physiologic variables,
anxious patients with AMI had less baroreflex cardiac
control than nonanxious patients, placing them at
increased risk for dysrhythmias.25 Further, patients
with HF exhibit reduced heart rate variability (HRV),26
attributable, in part, to high sympathetic activity.27
Depressed HRV independently predicts morbidity and
mortality for patients with HF.28
Others hypothesized that behavioral mechanisms,
such as nonadherence to treatment, link anxiety and
cardiac disease. Compared with nonanxious persons,
those with high anxiety may consume an unhealthy
diet, smoke, use drugs or alcohol, fail to adhere to
therapy, or be physically inactive.19,29,30 Anxious
patients with AMI experience problems coping with
challenges, which may adversely affect adherence to
treatment and rehabilitation efforts.31 Nonetheless, no
investigators, to the best of our knowledge, have
directly examined the hypothesized links of anxiety,
SNS arousal, and poor treatment adherence with clin-
ical outcomes for patients with HF.
This study investigated the relationship between
anxiety and event-free survival for patients with HF,
and examined whether behavioral or physiologic
mechanisms mediate any associations between
anxiety and outcomes. We hypothesized that (1)
patients with HF and high anxiety would manifest
worse event-free survival than patients with HF and
low anxiety, and (2) SNS arousal and nonadherence to
prescribed treatments would mediate the association
between anxiety and event-free survival.
Materials and Methods
Design
This substudy was planned a priori as part of
a prospective study to assess the relationship between
depression and outcomes for patients with HF. The
Institutional Review Board, University of Kentucky,
approved the study, and all subjects gave written,
informed consent.
Sample and Setting
Adult outpatients from a university-based medical
center and its clinics and a private hospital located in
the Midwestern United States were recruited for the
study. Providers referred patients to the researchers,
and the researchers posted signs and fliers about the
study in outpatient clinics. Patients were eligible to
enroll if they had a confirmed diagnosis of chronic HF,
as confirmed by a physician using established criteria
widely used by researchers.32,33 In addition, all eligible
patients had undergone an evaluation of their HF, were
receiving stable doses of drug therapy, had not been
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referred for urgent heart transplantation, and read and
spoke English. Patients were excluded if they had: (1)
HF attributable to valvular heart disease, myocarditis
or other inflammatory processes, or pregnancy; (2) a
history of cerebral vascular accident within the
preceding 3months, or chronic major sequelae such as
an inability to communicate or persistent hemiplegia
or paraplegia; (3) an AMI infarction within the past
3 months; (4) a coexisting terminal illness; (5) a major
psychiatric disorder, such as schizophrenia, that had
been diagnosed by a clinician and that interfered with
a patient’s ability to answer questions, engage in
a longitudinal study, or care for oneself; and (6)
impaired cognition. Patients with symptoms of
depression or anxiety were not excluded.
Measures
Anxiety
Anxiety was assessed using the anxiety subscale of the
Brief Symptom Inventory (BSI).34 The 6-item anxiety
subscale includes brief descriptions of psychological
symptoms that are associated with anxiety. Using
a scale from 0 (“not at all”) to 4 (“extremely”), partici-
pants rate their level of distress concerning these
symptoms. The 6 items are averaged. The averaged
score quantifies the patient’s level of anxiety, and can
range from 0 to 4. Higher scores denote higher anxiety.
The normative value for healthy adults is .35  .45.
However, normative data are unavailable for patients
with HF or other cardiac disorders.34 The subscale
contains no physiologic indices of anxiety, such as
heart rate or diaphoresis, that could spuriously over-
estimate measurements of anxiety in patients with
physical disease. Evidence supporting the validity of
each subscale of the BSI was reported.34 Investigators
reported that Cronbach’s a ranged from .85 to .90 in
patients with cardiac disease.18,35,36 In this study,
Cronbach’s a coefficient for the BSI was .85.
SNS Arousal
Heart-rate variability is a noninvasive measure of
autonomic nervous system tone. Patients with HF
typically exhibit decreased HRV, related to high levels
of sympathetic activity and decreased para-
sympathetic activity.27,37 Heart-rate variability was
measured in the time and frequency domains,38 and
assessed using data from 3-channel, 2-hour Holter
(DigiCorder 483, Del Mar Avionics, Irvine, CA) electro-
cardiogram recordings. A 2-hour recording is long
enough to accurately measure and assess HRV.39
Recordings were scanned in semiautomatic mode
(with operator verification of all beat types) on a Del
Mar 373 Holter Analysis System Scanner (Del Mar
Avionics). The data from these recordings included
time of beat, type of beat, serial RR intervals (also
termed normal-to-normal [NN] intervals) in millisec-
onds, and standard deviations of normal sinus RR
intervals in 5-minute epochs for the 2-hour recording
period. To demonstrate interrater and intrarater reli-
ability, 2 members of the study team reviewed the
recordings and scanned them twice. The members
achieved identical findings for 90% of the recordings.
When results differed, the members rescanned
the recordings to review and resolve areas of
disagreement.
Time-domain analyses are statistical calculations of
RR intervals. Time-domain measures included stan-
dard deviations of all NN intervals for a selected time
period (SDNN), and square roots of the mean squared
differences of successive NN intervals.38
For frequency-domain (or spectral) analysis, fast
Fourier transformation was used to apportion the HRV
signal into its frequency components, and to quantify
thepowerof these components.38 Two frequencybands
were of clinical interest: (1) the low-frequency (LF) band
(.04 to .15 Hz), and (2) the high-frequency band (.15 to .4
Hz).38 In humans, LF and HF peak frequencies are
commonly centered around about 0.1 Hz and 0.25 Hz,
respectively. The area under the curve of each
frequency band represents the powerwithin that band.
Total power represents the variability of the entire
signal, and is obtained by summing the powers of each
frequency band. Low-frequency and HF power also
were “normalized” (ie, expressed as a percentage of
total power).38 The reliability and validity of this
method for reflecting autonomic nervous system tone
in cardiac patients were demonstrated.38 To perform
frequency-domain analysis, the recording period was
divided into consecutive 5-minute epochs.38 An
instantaneous heart rate function was sampled
at 256-millisecond intervals, and smoothed using
a 584-millisecond boxcar filter.40 When an artifact or
any non-normal complex occurred, the preceding and
succeeding RR intervals were excluded from the anal-
ysis, and the instantaneous heart rate function was
Figure 1 e Proposed physiologic and behavioral
pathways linking anxiety and adverse outcomes.
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estimated according to linear interpolation.38 The
entire 5-minute segment was excluded from analysis if
more than 95% of the RR intervals were not NN inter-
vals. The mean NN interval was subtracted from the
sampled heart rate data, and a Hanning window was
applied.40 A fast Fourier transformwas then computed,
resulting in an absolute 5-minute power spectrum.
Plasma norepinephrine, a second measure of SNS
arousal used in this study, provides a standard
biochemical method of assessing the severity of SNS
activation, and was shown to predict mortality in HF.22
To ensure validmeasurements, each blood sample was
obtained under several conditions, to control for
factors that extraneously affect norepinephrine
release: (1) blood was drawn through a catheter that
was placed at least 30 minutes before sampling, to
avoid the pain and anxiety associated with venipunc-
ture; (2) patients remained in the same semi-fowlers
position for 30 minutes before the blood draw; (3)
patients were asked to refrain from caffeine, alcohol,
and nicotine for at least 8 hours before data collection;
(4) the room was comfortably warm and quiet, with
minimal interruptions; and (5) the collection of data
was conducted at the same time of day (1300 to 1500
hours).41 Blood was collected into centrifuge blood
tubes containing ethylenediaminetetraacetic acid (an
anticoagulant), immediately placed on ice, and centri-
fuged at 4C. Specimens were stored in single-use
aliquots at 80C until the time of analysis. Plasma
concentrations were determined using the Bi-Cat
ELISA kit (American Laboratory Products Company,
Windham, NH). Mean intra-assay and interassay
coefficients of variation for the laboratory were <8%,
indicating reproducible and valid measurements.
Adherence
Objective evidence of dietary adherence wasmeasured
using 24-hour urine sodium levels. Patients received
urinals, urine collection hats, and urine jugs, as well as
written and oral instructions regarding how to collect
urine for 24 hours. Patients were instructed to record
the time and amount of each void in their urination log.
Either a member of the research team visited the
patient’s home to pick up the 24-hour urine collection,
or the patient returned the collection to a member of
the research team, usually in conjunction with another
appointment. In either case, the team member
reviewed the urine log for completeness with the
patient.
A 2 to 3-g sodium diet is recommended for patients
with mild HF.42 Dietary sodium is absorbed and
subsequently secreted. Urinary sodium represents
approximately 86%43 to 95%44 of sodium intake,
depending primarily on the amount of perspiration.
Most patients with HF do not engage in strenuous
physical activity that produces significant perspiration.
Therefore, urinary sodium represents approximately
95% of sodium intake. Thus, urinary sodium at 2.85 g
(123 mmol), which is 95% of 3 g, was used to define
adherence to a sodium-restricted diet.
Objective evidence of medication adherence was
measured using the Medication Event Monitoring
System (MEMS, AARDEX, Union City, CA). The MEMS
is a microelectronic device housed within the cap of
a medication vial. The MEMS records the date and
time when the patient removes the cap from the
medication vial and presumably takes the correct
dose of medication. In a diary, patients documented
additional cap removals related to medication refills
or other medication vial openings not associated with
intake of the medication, thus ensuring accuracy. The
MEMS collects real-time data that are later down-
loaded to a computer. Evidence supporting the val-
idity of the MEMS to assess HF patients’ adherence
with prescribed medications was reported.45-47 In
fact, the use of an electronic monitoring device has
become the preferred standard method to assess
adherence.48 Data were collected for 1 HF medication
(ie, an ACE inhibitor, diuretic, b-adrenergic blocker, or
digoxin) for each patient. The medication selected for
MEMS monitoring was one that the patient took twice
per day. If all medications were taken once daily,
however, the MEMS was used for the b-adrenergic
blocker. If no b-adrenergic blocker was prescribed,
the MEMS was used for the ACE inhibitor or angio-
tensin receptor blocker. Patients used the MEMS for 3
months, and were unable to access data stored
within the MEMS. We defined “medication adher-
ence” as the percentage of days on which correct
doses taken ([total number of days when dose was
taken/total number of days prescribed]  100).
“Acceptable adherence” was defined as 88%,
because Wu et al reported that this level of adherence
was most sensitive and specific in predicting event-
free survival.49
Procedure
The initial collection of data occurred at a research
center. Sociodemographic data (ie, age, education
level, gender, ethnicity, and marital status) and
clinical characteristics (ie, left ventricular ejection
fraction, comorbidities, smoking status, b-adren-
ergic blocker use, ACE inhibitor use, New York
Heart Association [NYHA] functional class) were
collected by patient interviews and medical record
reviews. Patients completed the BSI Anxiety
Subscale and questionnaires regarding demographic
information. Next, patients were placed in a semi-
fowlers position, a saline-filled butterfly access
device was inserted, cardiac leads were placed on
the patient’s chest, and 2-hour Holter monitoring
commenced. After 30 minutes, a plasma norepi-
nephrine blood sample was drawn. Patients
received written and verbal instructions on how to
collect a 24-hour urine specimen and use the MEMS
medication vial. Patients received a urine collection
set, and arrangements were made to obtain a urine
specimen.
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Three-Month Data Collection
Three months after the initial collection of data, the
patient returned theMEMS device by giving it to a study
team member during a home visit, delivering it during
a regularly scheduled clinic visit, or mailing it in
a prepaid package. Company-provided equipment was
used to download MEMS data to a personal computer.
Twelve-Month Data Collection
Twelve months after the initial collection of data,
a study team member reviewed patients’ medical
records, the hospital administrative record database,
death certificates, and patient diaries, and also inter-
viewed patients and family members to collect data
about rehospitalizations, emergency department (ED)
visits, and mortality. Patients were followed until
all had undergone their 12-month collection of data.
Thus, some patients were followed for longer than
12 months. The reliability and validity of outcome
measures were determined by having all investigators
examine the same record and comparing their
conclusions. In addition, the accuracy of classifying
events was ensured by using multiple methods to
determine whether and when an event occurred.
Data Analysis
Data were analyzed with SPSS software, version 16.0
(SPSS, Inc, Chicago, IL). For all analyses, P  .05 was
considered statistically significant. To test the first
hypothesis, patients were divided into quartile groups,
based on their BSI anxiety score. Because these anxiety
groups may have differed in some demographic and
clinical characteristics that needed to be controlled
statistically, baseline differences were examined using
either analysis of variance or linear by linear associa-
tion c2 tests (for dependent nominal variables), as
appropriate. Cox proportional hazard modeling was
used to assess whether anxiety predicted event-free
survival, while controlling for the potential covariates
of age, gender, left ventricular ejection fraction, NYHA
classification, ACE inhibitor use, and b-adrenergic
blocker use.
For the second hypothesis, a series of regression
models was used to determine whether SNS arousal or
adherence to prescribed treatments mediated any
relationship between high anxiety and event-free
survival. Mediation was considered to have occurred if
a significant relationship was evident between anxiety
and event-free survival that became nonsignificant
when themediator was included in themodel. The test
for mediation followed the steps outlined by Baron and
Kenny.50 In summary, the initial step tested whether
anxiety predicted event-free survival, as already
described to test the first hypothesis. The second step
tested whether anxiety predicted each potential medi-
ator (ie, dietary adherence and medication adherence),
usingmultiple regression. Thenext step testedwhether
the mediators predicted event-free survival (using Cox
regression), and finally whether anxiety and the
potential mediator variables predicted event-free
survival when entered together into the model. Media-
tion was present if, in the final regression, a mediator
predicted the outcome, and the P value testing the
relationship between anxiety and outcomes was less
significant than the P value in the first step.
Results
Characteristics of the Sample
Characteristics of the sample are summarized in
Table 1. The average age of the 147 participants was
61  11 years, standard deviation (SD), and nearly one
third were women (30%). Over half of the participants
were married (61%), and the majority was Caucasian
(88%).
Anxiety and Event-Free Survival
The mean anxiety score was .71  .74 (SD), and 79
(54.1%) patients reported higher anxiety than the
Table 1 e Sample demographic and clinical
characteristics (n[ 147)
Characteristic
Age (years) 61  11 (SD)
Education (years) 13  3 (SD)
Women, n (%) 44 (30)
Ethnicity
Caucasian, n (%) 130 (88)
Black, n (%) 16 (11)
Hispanic or Latino, n (%) 1 (1)
Marital status
Married/cohabitating, n (%) 90 (61)
Widowed, n (%) 24 (16)
Divorced/separated, n (%) 19 (13)
Single, n (%) 14 (10)
Left ventricular ejection fraction (%) 35  14 (SD)
Previous acute myocardial
infarction, n (%)
85 (58)
Previous coronary arteries
bypass grafting, n (%)
51 (35)
Previous hypertension, n (%) 113 (77)
History of diabetes, n (%) 70 (48)
Current smoker, n (%) 28 (19)
Prescribed b-adrenergic blocker, n (%) 131 (89)
Prescribed angiotensin-converting
enzyme inhibitor, n (%)
106 (72)
New York Heart Association
classification
I, n (%) 9 (6)
II, n (%) 47 (32)
III, n (%) 65 (44)
IV, n (%) 22 (15)
SD, Standard deviation.
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reference norm of .35 for healthy adults. Based on the
distribution of anxiety scores, subjects were stratified
into 4 groups (Table 2), from lowest anxiety to highest
anxiety, to facilitate Cox proportional hazard
modeling. The 4 groups are not strict quartiles, because
30% of the patients reported no anxiety. No differences
in sociodemographic or clinical variables were evident
among the 4 anxiety groups.
The mean follow-up time to first event was 389 
324 days (SD). The first-event outcomes shown in Table
3 were used for event-free survival analyses. The data
confirmed the first hypothesis. Cox proportional
hazard modeling revealed that after adjusting for age,
gender, NYHA class, left ventricular ejection fraction,
ACE inhibitor use, and b-adrenergic blocker use, high
anxiety independently predicted event-free survival
(Figure 2 and Table 4). Patients in the highest anxiety
group were more likely to visit the ED, to be hospital-
ized, or to die, compared with those in the 3 lower
anxiety groups (hazard ratio, 2.2; 95% confidence
interval [CI], 1.1 to 4.3; P ¼ .03).
SNS Arousal as Mediator
The mean plasma norepinephrine level was .36  .23
nmol/L. The norepinephrine level was not related to
anxiety, adherence, or any measures of HRV except
SDNN (Table 5).
Heart-rate variability monitoring was performed in
65 subjects but was contraindicated in the remaining
subjects, who exhibited atrial fibrillation or paced
cardiac rhythms. As expected, the distribution of LF
and HF power was positively skewed. Therefore, these
values were log-transformed from the .04 to .15 Hz and
from the .15 to .4 Hz frequency bands, respectively. The
time-domain and frequency-domainmeasurements of
HRV are shown in Table 6. No measures of HRV, except
for SDNN, were correlated with anxiety, adherence, or
norepinephrine level (Table 5).
Given the lack of association between both anxiety
and plasma norepinephrine level, and anxiety and HRV
(Table 5), the data did not support the hypothesis that
SNS arousal mediates the association between anxiety
and event-free survival.
Nonadherence as Mediator
Urinary sodium levels from the 24-hour urine spec-
imen reached 196.27  92.26 mmol/day, which
computes to an average daily sodium intake of
4512.18  2121.11 mg/day. Of the 141 patients (95.9%)
with a useable 24-hour urine sample, 24% manifested
a computed sodium intake of 3 g. No association
between anxiety and dietary adherencewas evident, as
measured by 24-hour urine sodium level (Table 5).
Thus, we did not use dietary adherence in any further
mediation tests.
The MEMS data were available for 135 patients
(91.8%). Subjects used the MEMS for 1 of their
prescribed medications for an average of 94  18 days.
Based on date and time data from the MEMS, patients
took the correct number of doses on 80.6%  22.8%
days. Individually, 56% of patients took the correct
number of doses on 88% of the days that they used
the MEMS. Medication adherence was correlated with
anxiety (Table 5).
Data regarding objectively measured medication
adherence demonstrated that medication adherence
mediated the relationship between anxiety and event-
free survival, thus partially supporting the second
hypothesis. To demonstrate a mediation effect of
medication adherence, it is first necessary for anxiety
to predict event-free survival. This finding was evident
in the Cox regression already described, and was
shown in Figure 2. Further demonstration of mediation
requires evidence that anxiety predicts adherence to
medication. The regression analysis in Table 7
demonstrates this relationship. It is then necessary to
demonstrate a relationship between medication
adherence and event-free survival. Figure 3 shows that
after adjusting for age, gender, NYHA class, left
ventricular ejection fraction, ACE inhibitors, and b-
adrenergic blockers, adherence to medication inde-
pendently predicted event-free survival (P ¼ .001).
Patients who took the correct number of doses
on <88% of days were twice as likely (95% CI, 1.2 to 3.3;
P ¼ .008) to experience the combined endpoint. The
final step in demonstrating mediation involves
showing, in a regression that includes both anxiety and
medication adherence, that the effect of anxiety on
event-free survival has an associated P value that is
higher (less significant) than the P value for the rela-
tionship between anxiety and event-free survival
when anxiety is entered as a predictor without adher-
ence. Tables 4 and 8 show that adherence to medica-
tion mediated the relationship between anxiety and
poorer HF outcomes, because the effect of anxiety on
Table 2 e Mean anxiety score by quartile
Group n Mean BSI score
Lowest quartile (0% to 30%) 43 .00  .00
Second quartile (31% to 50%) 31 .30  .13
Third quartile (51% to 75%) 33 .84  .13
Highest quartile (76% to 100%) 39 1.73  .51
BSI, Brief Symptom Inventory.
Table 3 e First-event outcomes at follow-up point
Outcome n (%)
Death because of heart failure 2 (1.4)
Other cause of death 1 (.7)
Hospitalization for heart failure 10 (6.8)
Hospitalization for cardiac disease 23 (15.6)
Other cause of hospitalization 29 (19.7)
Visit to emergency department because
of heart failure
2 (1.4)
Visit to emergency department because of cardiac
disease
4 (2.7)
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event-free survival was less significant (P ¼ .17) when
the regression model included both anxiety and
medication adherence than when the model only
included anxiety (P ¼ .03).
Discussion
To our knowledge, this is the first study to show that
anxiety predicts event-free survival for patients with
HF, and that medication adherence behavior mediates
this relationship. The findings are unique because,
unlike others,51,52 we found that high anxiety inde-
pendently predicted clinical outcomes. Although
anxiety has contributed to poor outcomes for patients
with other cardiovascular disorders,18,19 this new
evidence shows that high anxiety and nonadherence to
prescribed medications help explain untoward
outcomes for patients with HF that cannot be fully
accounted for by sociodemographic or clinical vari-
ables. These data indicate that it is critical for clinicians
to assess anxiety in all patients with HF.
These results alignwith past findings indicating that
patients with HF have high levels of anxiety. In fact,
patients with HF were shown to be more anxious
than patients with other cardiac disorders.53,54 Sources
of anxiety for patients with HFmay include progressive
and debilitating physical symptoms with a poor long-
term prognosis; complex medication, dietary, and
activity treatment regimens; comorbidities; recurring
hospitalizations; hopelessness and loss of control; the
failure of usual coping mechanisms; isolation from
family and friends; frustrations with a complicated
healthcare system; financial worries; and fear of death.
The rates of nonadherence to prescribed medica-
tions for patients in this study, consistent with
previous research,55,56 revealed that individual patient
adherence remains problematic. Measured objectively
Figure 2 e Cox survival plot of anxiety by quartile and event-free survival.
Table 4 e Adjusted hazard ratios for the prediction
of event-free survival from anxiety, controlling for
age, gender, use of medications, left ventricular
ejection fraction, and New York Heart Association
classification (n[ 147)
Hazard
Ratio
95%
Confidence
Interval
P
Value
Age 1.015 .991 to 1.039 .22
Gender .851 .490 to 1.480 .57
Prescribed angiotensin-
converting enzyme
inhibitor
.626 .351 to 1.118 .11
Prescribed b-adrenergic
blocker
.472 .218 to 1.022 .06
Left ventricular ejection
fraction
.987 .968 to 1.007 .22
New York Heart
Association
classification
1.2 .712 to 2.023 .49
Second anxiety quartile* 1.146 .523 to 2.511 .73
Third anxiety quartile* .814 .383 to 1.729 .59
Fourth anxiety quartile* 2.167 1.091 to 4.304 .03
Omnibus test of model coefficients, c2 ¼ 23.79, P ¼ .005.
* Compared with lowest quartile of anxiety.
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for 3 months, only 56% of patients took the correct
number of medication doses on88% of the days when
they used the MEMS. Anxiety predicted adherence to
medication. Nonadherence may be related to
disagreements about the treatment regimen, the side
effects of medications, complex dosing schedules,
multiple medications, concerns about the effective-
ness of medications, improved symptoms, attitudes
about the importance of the medication, the cost of
medications, and self-care deficit, all of which may be
associated with anxiety.57,58 Although the exact
mechanism by which anxiety is related to adherence
remains unknown, anxiety may impair patients’
cognition, ability to learn, energy, motivation,
and willingness and ability to adhere to treatment.31
Further research is needed to elucidate how
anxiety, a complex and distressing emotion with
psychological, physiologic, behavioral, and cognitive
manifestations, affects adherence to medications or
other interventions that are commonly prescribed for
patients with HF.
The objective measure of dietary adherence, the 24-
hour urine sodium level, did not predict outcomes or
mediate the relationship between anxiety and
outcomes. This may be because we measured urine
sodium level once. In contrast, we measured adher-
ence to medication for 3 months.
Unlike others, we found no relationship between
anxiety and measures of SNS arousal. Likewise, HRV
arousal did not predict outcomes, likely because of the
low number of patients eligible for HRV monitoring. In
addition, most patients in this study were receiving
b-adrenergic blockers and ACE inhibitors, which
were shown to affect HRV and perhaps diminish
autonomic nervous system and neurohormonal
disturbances.59,60 Although b-adrenergic blockers were
shown to affect HRV,60 we enrolled patients receiving
these medications because b-adrenergic blockers are
the standard of care for patients with HF.42,61
Researchers were criticized for enrolling patients who
are not representative of the typical patient with
a given condition.62 Thus, to avoid this pitfall, which
would diminish our ability to generalize findings to the
typical patient with HF, we enrolled patients who took
b-adrenergic blockers. In addition, it would have been
unethical to discontinue these therapies, and difficult
to enroll sufficient numbers of patients who, for
whatever reason, do not take these medications.
Practice guidelines for the management of HF
mention the importance of adherence to medication,
but ignore the assessment and management of
anxiety, and do not include detailed recommendations
Table 5 e Correlations between anxiety level, plasma norepinephrine level, dietary adherence, adherence to
medications, and measures of heart rate variability
Anxiety
level*
Dietary
adherencey
Adherence to
medicationz
Plasma
norepinephrinex
Anxiety level (n ¼ 146) .04; P ¼ .67 .18; P ¼.04 .10; P ¼ .26
Dietary adherence (n ¼ 141) .04; P ¼ .67 .15; P ¼ .11 .05; P ¼ .57
Adherence to medication
(n ¼ 135)
.18; P ¼.04 .15; P ¼ .11 .01; P ¼ .96
Plasma norepinephrine level
(n ¼ 143)
.10; P ¼ .26 .05; P ¼ .57 .01; P ¼ .96
SDNN (n ¼ 65) .13; P ¼ .30 .01; P ¼ .97 .17; P ¼ .22 .26; P ¼ .03
RMSSD (n ¼ 65) .21; P ¼ .08 .17; P ¼ .18 .08; P ¼ .56 .08; P ¼ .50
LF nu (n ¼ 65) .10; P ¼ .41 .15; P ¼ .26 .22; P ¼ .12 .07; P ¼ .61
HF nu (n ¼ 65) .10; P ¼ .41 .15; P ¼ .26 .22; P ¼ .12 .07; P ¼ .61
Log LF (n ¼ 65) .09; P ¼ .49 .15; P ¼ .25 .14; P ¼ .30 .17; P ¼ .18
Log HF (n ¼ 65) .003; P ¼ .98 .06; P ¼ .64 .01; P ¼ .95 .20; P ¼ .12
Log LF/HF ratio (n ¼ 65) .15; P ¼ .24 .15; P ¼ .25 .21; P ¼ .13 .01; P ¼ .95
LF, low frequency;HF, high frequency; nu, normalized units; RMSSD, square root of themean squared differences of successive
NN intervals; SDNN, standard deviation of all NN intervals.
*Measured at the continuous level.
yReflected by 24-hour urine sodium excretion.
zAdherence as percentage of days when correct doses were taken.
xMeasured at the continuous level.
Table 6 e Mean time-domain and frequency-
domain measurements of heart rate variability
(n[ 65)
Time domain
SDNN (milliseconds) 56  26
RMSSD (milliseconds) 32  20
Frequency domain
LF 248.9  392.1
HF 241.4  339.5
LF nu 49.8  21.1
HF nu 50.2  21.1
Log LF 4.6  1.4
Log HF 4.9  1.2
Log LF/HF ratio 1.0 .2
LF, low frequency; HF, high frequency; nu, normalized
units; RMSSD, square root of the mean squared differences
of successive NN intervals; SDNN, standard deviation of all
NN intervals.
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on how to improve adherence to medication.42
Hundreds of clinical trials were conducted to test
interventions designed to improve adherence for
patients with cardiovascular or other chronic disor-
ders. In summary, adherence to medication and
outcomes were shown to improve with physician-
supervised, nurse-mediated, home-based manage-
ment strategies; patient education and discharge
planning; reminder cards, calls, or alarms; improved
medication container designs; improved patient
communication with clinicians; improved dosing
schedules; extended clinic hours; the prescription
of once-daily formulations or “polypills;” positive
reinforcement; electronic monitoring systems; social
support; and patient-centered medication instruc-
tions.58,63-65 In a previous study, married patients were
more likely to be adherent than patients without
a spouse, indicating that interventions designed to
improve adherence should include the patient’s
spouse.66 However, the guidelines fall short when, at
best, they encourage clinicians to consider the
patient’s psychological state when deciding how to
educate and manage patients. No recommendations
are available on assessing anxiety or initiating inter-
ventions to reduce anxiety. Similarly, recent reviews
and clinical studies contain a plethora of strategies
that clinicians can use to improve adherence, but
omit mention of anxiety.57,58,67 Importantly, our find-
ings indicate that anxiety predicts adherence to
medication, which in turn mediates the relationship
between high anxiety and worse outcomes.
Limitations
Four limitations of this study exerted the greatest
impact on our findings. First, more subjects than
expected manifested atrial fibrillation or paced cardiac
Table 7 e Multiple regression of demographic, clinical, and anxiety variables associated with adherence to
medications (percentage of days when correct number of prescribed doses was taken) (n[ 147)
Predictor
variables
Step F Step
P value
R2 Adjusted
R2
F for change
in R2
P value for
change in R2
Standardized
b
b
P value
Step 1 2.64 .052 .06 .04 2.64 .052
Age .07 .44
Gender .10 .27
NYHA class .20 .02
Step 2 3.61 .008 .10 .08 6.20 .01
Age .01 .91
Gender .09 .33
NYHA class .17 .06
BSI anxiety score .22 .01
BSI, Brief Symptom Inventory; NYHA, New York Heart Association.
Figure 3 e Cox survival plot of adherence to medications and event-free survival.
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rhythm, preventing HRV analyses of these subjects.
Second, we used the documented admission diagnosis
in each subject’s medical record for first-event
outcomes. We did not anticipate a large number of
nonspecific diagnoses, such as edema and shortness of
breath, that were consistent with a diagnosis of HF but
not documented as such. As a result, we classified
more subjects than expected as “other hospitaliza-
tion.” Third, the sample size was small, but nonethe-
less adequate to demonstrate a relationship between
anxiety and event-free survival. We recommend that
future investigators conduct a larger study to confirm
or refute our findings, and to test the best strategies for
improving adherence. Fourth, although the ethnicity of
the sample reflects the patient population where the
study was performed, the sample lacks racial diversity.
Conclusions
We found that anxiety predicted event-free survival for
patients with HF, and that adherence to medication
mediated this relationship. Although causality cannot
be inferred fromourdata, our results suggest that itmay
be important for clinicians to assess medication
adherence objectively for patients with HF, and to
consider customizing interventions according to
patient needs and preferences. An assessment of
adherence to medication should be included in clinical
practice guidelines for the management of patients
with HF. Nearly all patients used the MEMS without
difficulty, and were accepting of it. Objective assess-
ment of adherence tomedication in allpatientsmaynot
be feasible or cost-effective. Nonetheless, our findings
indicate that clinicians are obliged to pay special
attention to medication adherence, especially among
highly anxious patients and those who frequently
requirehospitalizations or visit the ED. If nonadherence
is suspected, the MEMS offers an attractive method of
assessment. Further, the approximate $100 cost of the
MEMS is justified if nonadherence is corrected and
hospitalizations or ED visits are avoided.
In conclusion, themediation effect of nonadherence
to prescribed medications on the relationship between
anxiety and outcomes adds to the body of research.
The astute assessment of anxiety and adherence to
medication merits increased attention from clinicians
who manage patients with HF, because adherence to
medication helps explain how anxiety is associated
with adverse outcomes. Although we did not conduct
a randomized trial to test intervention strategies in
patients with differing levels of anxiety, the findings of
this study indicate a need for such research, particu-
larly among patients with the highest levels of anxiety.
Interventions designed to reduce anxiety and improve
adherence to prescribed medications may improve
outcomes.
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